| Professional Services Industry | Industrials Sector | Robert Louis Thast CEO | XMUN Exchange | CA46604F1099 ISIN |
| CA Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Izotropic Corporation operates within the medical device industry focusing on the innovation and commercialization of diagnostic solutions primarily for breast cancer detection. Established in 2016 and based in Surrey, Canada, the company has dedicated its efforts to developing advanced imaging technologies to improve the clarity, accuracy, and efficiency of breast cancer diagnostics. Recognizing the critical need for early and accurate breast cancer detection, Izotropic Corporation aims to be at the forefront of medical imaging technologies, thus contributing significantly to the field of diagnostic medicine.
An innovative diagnostic tool under development by Izotropic Corporation is the IzoView, a 360-degree computed tomography (CT) imaging system. This state-of-the-art system is exclusively designed for breast imaging, aiming to set a new standard in the detection and diagnosis of breast cancers. By offering comprehensive 360-degree scans, IzoView seeks to provide unparalleled clarity and detail, potentially identifying tumors and abnormalities that traditional mammography may miss. The development of IzoView represents Izotropic Corporation's commitment to advancing medical imaging technologies and improving the outcomes of breast cancer diagnostics.